Nachrichten zur Intra-Cellular Therapies Aktie

Intra-Cellular Therapies: Parkinsons Disease Drug Expansion Could Be The Next Huge Move

…

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

…

Intra-Cellular Therapies: Downgrade

Zürich (www.aktiencheck.de) - Rating-Update: Die Analysten der UBS stufen die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN: A1XDTL, Ticker-Symbol: 23I,…

Intra-Cellular Therapies: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Mizuho Securities USA bewerten die Aktie von Intra-Cellular Therapies Inc. (ISIN: US46116X1019, WKN:…

Intra-Cellular Therapies: Klares Upside-Potenzial - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Intra-Cellular Therapies-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy

…

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript

…

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term Buy

…

Intra-Cellular Therapies has analysts bullish on strong sales trajectory and likely success of depression study

Intra-Cellular Therapies has earned an ‘Outperform’ rating in its initial coverage from Baird analysts who believe the biotechnology company’s strong…

Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?

Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Intra-Cellular Therapies gains amid repeated takeover speculation

…

Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript

…

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 27.42% and 3.97%, respectively, for the quarter ended June 2023. Do the…

Form 10-Q Intra-Cellular Therapies For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022...…

Intra-Cellular Therapies Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Intracellular Th im Wert von 119.730$

Durgam, Suresh K. - Vorstand - Tag der Transaktion: 2023-07-17...…

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the…

Form 10-Q Intra-Cellular Therapies For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022...…

Intra-Cellular Therapies Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…

Insiderhandel: Aufsichtsrat verkauft Aktien von Intracellular Th im Wert von 630.000$

Van Nostrand Robert L. - Aufsichtsrat - Tag der Transaktion: 2023-04-17...…

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 847.380$

Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-28...…

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock…

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features

read more...…

Why Intra-Cellular Therapies Climbed Tuesday

The companys depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression....…

Pre-market Movers: Viking Therapeutics, Immuneering, Oscar Health, WiSA Technologies, Intra-Cellular Therapies

LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesdays pre-market trading (as of 08.15…

Intra-Cellular jumps 14% after early data for depression candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intra-Cellular’s stock jumps on new data for depression drug

Shares of Intra-Cellular Therapies Inc. ITCI jumped about 15% in premarket trading on Tuesday after the company said its experimental…

Form 8-K Intra-Cellular Therapies For: Mar 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 370.557$

Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-10...…

Insiderhandel: EVP and General Counsel verkauft Aktien von Intracellular Th im Wert von 720.086$

Halstead, Michael - Vorstand - Tag der Transaktion: 2023-03-10...…

Insiderhandel: EVP, Chief Medical Officer verkauft Aktien von Intracellular Th im Wert von 330.794$

Durgam, Suresh K. - Vorstand - Tag der Transaktion: 2023-03-13...…

Insiderhandel: EVP and General Counsel verkauft Aktien von Intracellular Th im Wert von 330.006$

Halstead, Michael - Vorstand - Tag der Transaktion: 2023-03-13...…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intracellular Th im Wert von 169.042$

Neumann, Mark - Vorstand - Tag der Transaktion: 2023-03-13...…